1 min read

A reference product is a medicinal product used as a benchmark in regulatory evaluations to compare the quality, safety, and performance of another product, typically a generic version.

According to internationally recognized guidelines, including those from the World Health Organization, the reference product serves as the comparator in studies designed to demonstrate equivalence between pharmaceutical products.

In most cases, it corresponds to the original innovator drug or a product recognized by regulatory authorities as a suitable comparator for regulatory and scientific purposes.

What Is the Role of a Reference Product in Regulatory Processes?

The reference product plays a central role in demonstrating equivalence between medicines.

It serves as the benchmark against which other products are evaluated in order to:

  • Compare bioavailability and pharmacokinetic profiles
  • Support the demonstration of bioequivalence
  • Establish therapeutic interchangeability

In most cases, the absence of a defined comparator limits the ability to conduct comparative studies required for the regulatory evaluation of generic medicines.

How Is the Reference Product Concept Applied in Colombia?

In Colombia, this concept is applied within the regulatory framework overseen by INVIMA, particularly in the context of bioequivalence requirements.

Although Colombian regulations do not always provide a single explicit definition of “reference product,” the concept is operationalized through bioequivalence guidelines and regulatory practices.

In this context, the comparator is typically:

  • The innovator product authorized in a recognized market
  • A product identified by the regulatory authority for comparison purposes
  • A benchmark used in bioequivalence studies to support approval

Why Does the Reference Product Matter in Colombia?

The reference product is essential to ensuring that generic medicines meet the required standards for quality, safety, and efficacy.

Its role is particularly relevant in cases where bioequivalence is required, as it defines the benchmark for comparison.

In Colombia, where bioequivalence requirements are applied selectively based on specific product categories, this concept becomes a key element in determining whether a generic medicine can be considered interchangeable.

Key Considerations for Pharmaceutical Companies

When planning regulatory submissions in Colombia, companies should consider:

  • The selection of an appropriate reference product for comparative studies
  • The regulatory expectations defined by INVIMA
  • The relationship between reference product selection and bioequivalence requirements
  • The role of the reference product in demonstrating therapeutic equivalence

If your organization is preparing a regulatory submission in Colombia and needs clarity on reference product selection or bioequivalence requirements, connect with Freyr's team to define the right approach from the start.